5-Amino-1MQ Human Clinical Trials: 2026 Status and Fat Loss Mechanism

What 5-Amino-1MQ Is

5-Amino-1-methylquinolinium iodide (5-amino-1MQ) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). Despite appearing in peptide-focused clinical practice discussions, 5-amino-1MQ is not a peptide — it is a small molecule. Its inclusion in metabolic-medicine conversation reflects the growing willingness of physicians to consider mechanism-first compounds across classes.

NNMT is an enzyme that methylates nicotinamide, consuming S-adenosylmethionine (SAM) in the process. NNMT overexpression has been associated with metabolic dysfunction, obesity, and reduced NAD+ availability. Inhibiting NNMT has been proposed as a therapeutic strategy for metabolic disease.

5-Amino-1MQ Research at a Glance: Preclinical vs Human

5-Amino-1MQ is a small-molecule NNMT inhibitor from the methylquinolinium series. Everything known about its effects comes from cell and mouse studies. Several of the key papers come from one research group whose authors disclose ties to a company developing NNMT inhibitors [4][5].

Bottom line: the mechanism has solid preclinical support, but there are no human outcome data. What is and isn't known about side effects is covered in 5-Amino-1MQ side effects: heart rate, appetite and emerging safety data. For the compound profile, see the 5-Amino-1MQ research library page.

The Fat Loss Mechanism

The proposed fat loss mechanism of 5-amino-1MQ operates through several interrelated effects:

• NNMT inhibition preserves SAM and NAD+ pools
• Increased NAD+ supports sirtuin activity and mitochondrial function
• Reduced lipogenesis — adipocyte fatty acid synthesis is decreased
• Enhanced adipocyte metabolism — improved adipose tissue function
• Selective effect on adipocytes — relative sparing of other tissues

Preclinical studies have shown that 5-amino-1MQ treatment in mice produces:

• Reduced body fat mass
• Improved insulin sensitivity
• Preserved lean mass
• Favorable effects on liver fat in diet-induced obesity models

The Human Clinical Trials Picture

As of 2026, human clinical trial activity for 5-amino-1MQ is emerging but not yet mature. Key features of the current landscape:

• Academic and biotech interest has advanced the compound from early preclinical to translational work
• Phase 1 human trials on ClinicalTrials.gov: none found for 5-amino-1MQ in an October 19, 2026 search
• Published human efficacy data at the level of a completed, results-reported phase 2 study are not yet a settled part of the dataset

• Commercial development is active but has not produced a near-term approval path

Patients and clinicians tracking 5-amino-1MQ should monitor ClinicalTrials.gov and peer-reviewed publications for current status.

Why Compounding Access Is Not an Established Path

5-amino-1MQ is not on the FDA 503A bulk drug substances list. It is a research compound being developed through the conventional drug development pathway — not a compounding-pharmacy-accessible substance. Patients encountering 5-amino-1MQ outside of proper clinical trial enrollment are typically accessing research-grade material from non-clinical sources, which is not an appropriate pathway for physician-supervised use.

Positioning in the Metabolic Medicine Conversation

For physicians fielding patient questions about 5-amino-1MQ, the appropriate framing:

• Promising mechanism with solid preclinical rationale
• Early clinical development — human efficacy and safety not yet well characterized
• No legitimate clinical access pathway in the United States as of 2026
• Alternative evidence-based options exist for the underlying metabolic optimization goals patients typically pursue

Key Takeaways

• 5-amino-1MQ is a small-molecule NNMT inhibitor, not a peptide.
• The proposed fat loss mechanism operates through SAM and NAD+ preservation.
• Preclinical data support fat loss and metabolic benefits.
• Human clinical trial activity is emerging; completed efficacy trials are not yet established.
• There is no legitimate compounding or clinical access pathway in U.S. practice.
• Patients should be directed toward evidence-based alternatives for metabolic optimization.

Frequently Asked Questions

Has 5-amino-1MQ been tested in humans?

Human clinical trial activity is emerging but limited. Published human efficacy data are not yet mature.

How does 5-amino-1MQ reduce fat?

By inhibiting NNMT, which preserves SAM and NAD+ pools, supports sirtuin activity, and reduces adipocyte lipogenesis.

Can I get 5-amino-1MQ through a compounding pharmacy?

No. It is not on the FDA 503A bulk drug substances list.

Is 5-amino-1MQ safe?

Preclinical data have not shown prominent adverse effects, but human safety data are limited.

What is 5-Amino-1MQ?

5-Amino-1MQ (5-amino-1-methylquinolinium) is an experimental small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that is overexpressed in fat tissue in obesity. In mice, blocking NNMT raises NAD+ and SAM levels in fat cells and limits fat gain [3][4]. It is not FDA-approved for any use.

Is 5-Amino-1MQ a peptide?

No. 5-Amino-1MQ is a small molecule, a modified quinolinium ring with no amino-acid chain. It is often grouped with peptides because the same clinics and vendors discuss them together, but chemically and legally it is a separate category. See the FDA Peptide Status Tracker for regulatory context.

References

1. Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258-62. PubMed
2. Brachs S, et al. Genetic Nicotinamide N-Methyltransferase (Nnmt) Deficiency in Male Mice Improves Insulin Sensitivity in Diet-Induced Obesity but Does Not Affect Glucose Tolerance. Diabetes. 2019;68(3):527-542. PubMed
3. Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152. PubMed
4. Babula JJ, et al. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab. 2024;26(11):5272-5282. PubMed
5. Dimet-Wiley AL, et al. Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Sci Rep. 2024;14(1):15554. PubMed
6. Neelakantan H, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochem Pharmacol. 2019;163:481-492. PubMed